Importantly, recent studies have shown that although the frequency of CADASIL clinical cases is ~4 in 100,000, the actual prevalence of NOTCH3 variants affecting the number of cysteines is much higher than expected in the general population (~1 in 400) and associated with increased incidence of vascular dementia. Here, NOTCH3 is linked to vascular dementia.